Tisagenlecleucel
Product Specifications
CAS Number
1823078-37-0
UNSPSC Description
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma[1][2].
Target Antigen
CD19
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tisagenlecleucel.html
Solubility
H2O
Smiles
[Tisagenlecleucel]
References & Citations
[1]Bishop MR, et, al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2022 Feb 17;386(7):629-639. |[2]Fowler NH, et, al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022 Feb;28(2):325-332.
Shipping Conditions
Room temperature
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AP52670PU-N 400 µL
METT10D (METTL16) (C-term) Rabbit Polyclonal Antibody
Sign In for Pricing
View Details 
LC427007 20 µg
BRG1 (SMARCA4) (NM_001128849) Human Over-expression Lysate
Sign In for Pricing
View Details 
HA750229 100 µL
Mast Cell Tryptase Recombinant Rabbit monoclonal Antibody
Sign In for Pricing
View Details